Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study.
Document Type
Article
Publication Date
9-22-2021
Publication Title
Journal of infusion nursing : the official publication of the Infusion Nurses Society
Keywords
california; santa rosa
Abstract
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel. In the overall population (N = 34) and an elderly subgroup (n = 21), IV cetirizine was as effective as IV diphenhydramine in preventing infusion reactions (primary outcome) and associated with less sedation at all time points, a shorter infusion center stay, and fewer treatment-related adverse events.
Clinical Institute
Cancer
Department
Nursing
Department
Oncology
Recommended Citation
Holmes, Jarrod P; Peguero, Julio A; Garland, R Campbell; North, Janine; Young, Stacia; Brent, Lonnie D; and Joseph-Ridge, Nancy, "Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study." (2021). Articles, Abstracts, and Reports. 5292.
https://digitalcommons.providence.org/publications/5292
